Klinické štúdie Obézita v štáte Michigan
29 štúdií pre Obézita hľadá účastníkov v zariadeniach v štáte Michigan.
Mestá v štáte Michigan
Oficiálny text štúdie (anglicky)
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Revival Research Institute, LLC, Dearborn
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07783802Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- Profound Research, Farmington Hills
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07837973AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Northern Pines Hlth Ctr, PC, Buckley
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07720271A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Aa Mrc Llc, Flint
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07595549A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Helen Devos Childrens' Hospital - PIN, Grand Rapids
Prebieha náborFáza 3
Vek 6 až 17 · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06672549A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Great Lakes Research Institute, Southfield
- Revive Research Institute, Inc., Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Farmington Hills
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07784270A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Revive Research Institute, Inc., Southfield
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07369011A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Headlands Research - Detroit, Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Southfield
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- University of Michigan Health System, Dominos Farms, Ann Arbor
- Embassy Research Network, Bloomfield Township
- Henry Ford Health System, Detroit
- a 3 ďalších
Prebieha náborFáza 3
Vek 18 až 99 · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT07037459A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Headlands Research - Detroit, Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- David Fivenson, MD, PLC, Ann Arbor
- The Derm Institute of West Michigan, Caledonia
Prebieha náborFáza 4
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Farmington Hills
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Headlands Research - Detroit, Southfield
Prebieha náborFáza 3
Vek 18 až 99 · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT07684235Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Farmington Hills
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 9. 2026 · NCT07284979Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research Division, Troy
Prebieha náborFáza 3
Vek 18 až 99 · Všetky pohlavia · Aktualizované 27. 8. 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Troy
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT07784725Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- C.S. Mott University of Michigan, Ann Arbor
Prebieha náborFáza 2
Vek 7 až 25 · Všetky pohlavia · Aktualizované 19. 8. 2026 · NCT05082519A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Cardio and Vascular Assoc-CAVA, Bloomfield Hills
- Corewell Health, Grand Rapids
- University Of Michigan, Lansing
- a 2 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 8. 2026 · NCT07567001AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Arcturus Healthcare, PLC., Troy
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 8. 2026 · NCT07509307Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Ann Arbor
Prebieha náborFáza 3
Vek 18 až 79 · Všetky pohlavia · Aktualizované 10. 8. 2026 · NCT07654361Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance
- University of Michigan, Ann Arbor
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Vek 15 až 75 · Všetky pohlavia · Aktualizované 13. 7. 2026 · NCT02043457Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
- University of Michigan, Ann Arbor
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Vek 14 až 18 · Všetky pohlavia · Aktualizované 13. 7. 2026 · NCT06007404Michigan Weight Navigation Program (MiWeigh) Study
- University of Michigan, Ann Arbor
Prebieha nábor
Vek 18 až 75 · Všetky pohlavia · Aktualizované 12. 6. 2026 · NCT07465341Exercise Effects on Adipose Tissue Structure and Function
- University of Michigan, Ann Arbor
Prebieha nábor
Vek 18 až 40 · Všetky pohlavia · Aktualizované 4. 6. 2026 · NCT04812314Metabolic Adaptations to Weight Loss With and Without Exercise
- University of Michigan, Ann Arbor
Prebieha náborVítaní zdravých dobrovoľníkov
Vek 18 až 40 · Všetky pohlavia · Aktualizované 14. 4. 2026 · NCT05806801RESET System Pivotal Trial (Rev F)
- Michigan Medicine, Division of Gastroenterology and Hepatology, Ann Arbor
Prebieha nábor
Vek 22 až 65 · Všetky pohlavia · Aktualizované 18. 7. 2024 · NCT04101669Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.